Zyxel Networks Honored with Placement in the 2025 CRN Partner Program Guide
'We're continuously evaluating ways we can help our valued partners grow and expand their businesses through the various programs and benefits provided through our Zyxel Authorized Partner Program.' — David Soares, EVP Channel Sales and Marketing North America
ANAHEIM, CA, UNITED STATES, March 26, 2025 / EINPresswire.com / -- Zyxel Networks, a leader in delivering secure, AI- and cloud-powered business and home networking solutions, has been honored by CRN ®, a brand of The Channel Company, with inclusion in the prestigious 2025 CRN Partner Program Guide. This annual guide is an essential resource for solution providers seeking vendor partner programs that match their business goals and deliver high partner value.
The extensive support and resources technology vendors offer through their partner programs are a critical consideration for solution providers assessing which IT vendors, service providers, and distributors to team with in building world-class technology solutions. Program elements such as financial incentives, sales and marketing assistance, training and certification, technical support, and more can set vendors apart and play a key role in boosting their partners' long-term growth and profitability.
For the 2025 Partner Program Guide, the CRN research team evaluated vendors based on program requirements and offerings, such as partner training and education, pre-and post-sales support, marketing programs and resources, technical support, and communication.
Zyxel Authorized Partner Program provides solution providers with the tools and resources necessary to create and sell scalable enterprise-class networking solutions that meet the needs and budgets of the mid-market. The Zyxel Education Center offers training in network fundamentals and teaches partners how to manage a wide range of networking equipment effectively and can lead to certification as a Zyxel Certified Sales Associate, Zyxel Certified Network Associate, or Zyxel Certified Network Engineer. The company also implemented a program that helped Bronze Partners reach Silver Partner status faster enabling them to increase profitability through NFR/demo discounts and larger distribution discounts. Zyxel authorized partners receive generous discounts from authorized distributors to enhance margin and reward loyalty.
'We're continuously evaluating ways in which we can help our valued partners grow and expand their businesses through the various programs and benefits provided through our Zyxel Authorized Partner Program ,' explained David Soares, Executive Vice President Channel Sales and Marketing North America. 'Our robust portfolio of enterprise-class networking solutions combined with training resources, discounts, and technical and engineering support equip our partners with the ability to deliver fully integrated end-to-end network solutions that provide the opportunity to add managed services and increase profitability.'
'Being featured on the 2025 CRN Partner Program Guide highlights the dedication these technology vendors have to evolving with solution providers, driving innovation, and supporting mutual success,' said Jennifer Follett, VP, U.S. Content and Executive Editor, CRN, at The Channel Company. 'This critical annual project empowers solution providers to identify vendors that are committed to enhancing their partner programs and meeting the always-changing business needs of the channel and end customers. The guide provides deep insight into the distinctive value of each partner program so solution providers can make strategic partnership decisions with confidence.'
The 2025 Partner Program Guide will be spotlighted in the April 2025 issue of CRN and published online at www.CRN.com/PPG beginning March 24, 2025.
For more information about Zyxel, its connectivity solutions, and the Zyxel Authorized Partner Program, visit www.zyxel.com/us and follow us on Facebook, Twitter and LinkedIn.
About Zyxel:
Zyxel Networks is a technology provider with over 30 years of experience, specializing in delivering solutions for small to medium-sized businesses and the enterprise-edge in partnership with VARs, MSPs and System Integrators. We enable network professionals to connect and protect organizations with greater ease by bringing together intuitive, scalable and secure cloud management with a complete portfolio of network devices.
About The Channel Company:
The Channel Company (TCC) is the global leader in channel growth for the world's top technology brands. We accelerate success across strategic channels for tech vendors, solution providers, and end users with premier media brands, integrated marketing and event services, strategic consulting, and exclusive market and audience insights. TCC is a portfolio company of investment funds managed by EagleTree Capital, a New York City-based private equity firm. For more information, visit thechannelco.com.
Follow The Channel Company: X, LinkedIn and Facebook.
# # #
Ken Hagihara
Zyxel Networks
+1 949-796-3112
X
YouTube
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
5 hours ago
- Business Insider
MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
Shares in drug giant Moderna (MRNA) plummeted nearly 10% today after it reported a drop in Q2 sales. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company reported earnings for the period of -$2.13, beating expectations of -$3.03 but also recorded a 41.1% drop in year-over-year sales to $142 million. However, that still beat forecasts of $128.3 million. Sentiment Hit Investor sentiment was also hit by the company dropping its revenue guidance for the full year to $1.85 billion at the midpoint from $2 billion, a 7.5% decrease. It blamed the 'timing of shipments.' The decline was primarily driven by lower Spikevax COVID vaccine sales, which totaled $114 million in the quarter. Moderna said demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine continues to transition into a seasonal respiratory product. It also reported 'negligible' RSV vaccine mRESVIA® sales in the second quarter of 2025. The figures continue Moderna's difficult year in comparison with its peers – see below. 'In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'Looking forward, we have important catalysts over the next six months across our infectious disease and oncology programs that will help us deliver on the promise of our mRNA platform for patients.' Future Hopes This includes Intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK). This includes two non-small cell lung cancer Phase 3 studies and Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer. Cost of sales for 2025 is expected to be approximately $1.2 billion. Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion. Year-end cash and investments for 2025 are projected to be approximately $6 billion. Recently, Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The company anticipates a total headcount of less than 5,000 by the end of the year. Better news came today for the group after Pfizer (PFE) and its German partner BioNTech (BNTX) lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Business Wire
10 hours ago
- Business Wire
Align Technology President and CEO Joe Hogan Personally Purchases $1 Million of Align's Common Stock
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Joe Hogan, Align Technology president and CEO, has personally purchased approximately $1 million of Align's common stock. Since his last sale of Align common stock in 2021, Mr. Hogan has purchased approximately $8 million of Align common stock 1. 'This purchase reflects my continuing confidence in the long-term value of Align and our commitment to increasing shareholder value by balancing investments to drive growth and continuing to invest with discipline in the areas that will define our future,' said Joe Hogan, president and CEO. 'We are excited about our next-generation technologies and treatment platforms that meet today's patient expectations for fast, effective, and personalized treatment while also providing value and growth opportunities for our doctor customers. We believe that these innovations are not only improving outcomes in Invisalign practices but also expanding our addressable market and strengthening our competitive differentiation.' Continued Hogan, 'While we believe that the macroeconomic uncertainty will likely persist into the near future, we are confident in our ability to adapt and lead. Our long-term strategic initiatives and opportunities remain intact, as does our commitment to focused execution on transforming treatment for doctors and patients.' 1 Valued based on the purchase price of Align common stock at the time of each purchase. About Align Technology Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 286.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform, and iTero Lumina are trademarks of Align Technology, Inc.
Business Wire
12 hours ago
- Business Wire
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) ('KORU Medical' or the 'Company'), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the 'Freedom System') currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit
